ORGANOGENESIS HOLDINGS INC. Payments of Debt Issuance Costs
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Payments of Debt Issuance Costs of $924.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2021-03-16
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for the quarter ending 2019-12-31 was $0.00.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for the quarter ending 2019-09-30 was $75.00K, a 63.04% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for the quarter ending 2019-06-30 was $38.00K, a 68.85% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for the quarter ending 2019-03-31 was $811.00K, a 8911.11% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for fiscal 2019 was $924.00K, a 422.03% increase from fiscal 2018.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for fiscal 2018 was $177.00K, a 79.47% decline from fiscal 2017.
- ORGANOGENESIS HOLDINGS INC. payments of debt issuance costs for fiscal 2017 was $862.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $75.00K derived: sum of 2 quarters · filed 2021-03-16 | $113.00K derived: sum of 3 quarters · filed 2021-03-16 | $924.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $113.00K derived: sum of 2 quarters · filed 2020-11-09 | $924.00K 10-Q · filed 2020-11-09 | $924.00K derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $849.00K 10-Q · filed 2020-08-10 | $849.00K derived: sum of 3 quarters · filed 2021-03-16 | $895.00K derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-03-31 | $811.00K 10-Q · filed 2020-05-11 | $811.00K derived: sum of 2 quarters · filed 2021-03-16 | $857.00K derived: sum of 3 quarters · filed 2021-03-16 | $979.00K derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $46.00K derived: sum of 2 quarters · filed 2021-03-16 | $168.00K derived: sum of 3 quarters · filed 2021-03-16 | $177.00K 10-K · filed 2021-03-16 |
| 2018-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $168.00K derived: sum of 2 quarters · filed 2019-11-12 | $177.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $131.00K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $9.00K 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $862.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |